ArticleAnnals of the rheumatic diseases2022
Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques
Kristin M D'Silva, Naomi Serling-Boyd, Rachel Wallwork, Tiffany Y-T Hsu, Jeffrey A Sparks, Zachary Scott Wallace
Abstract readLetterComment
In one paragraphArticle in Annals of the rheumatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
6 authors.
Kristin M D'SilvaDivision of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA.
Naomi Serling-BoydDivision of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA.
Rachel WallworkDivision of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA.
Tiffany Y-T HsuDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Funding
VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYticsP30AR072577 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Daniel Hal Solomon · 2017 to 2026
$9.8MJoint Biology Consortium Resource-based CenterP30AR070253 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Peter A Nigrovic, Jeffrey Andrew Sparks · 2016 to 2026
$9.4MResearch Training in Rheumatology at Massachusetts General HospitalT32AR007258 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI ANDREW D LUSTER · 1986 to 2026
$6.9MImpact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated VasculitisK23AR073334 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI WALLACE, ZACHARY SCOTT · 2018 to 2022
$948kRheumatoid Arthritis and Respiratory Outcomes in Prospective CohortsK23AR069688 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SPARKS, JEFFREY ANDREW · 2016 to 2020
$766kRespiratory Diseases, Genetics, and Rheumatoid Arthritis RiskR03AR075886 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SPARKS, JEFFREY ANDREW · 2019 to 2020
$179kNIAMS NIH HHS K23 AR069688NIAMS NIH HHS K23 AR073334NIAMS NIH HHS L30 AR066953NIAMS NIH HHS L30 AR070520NIAMS NIH HHS P30 AR070253NIAMS NIH HHS P30 AR072577NIAMS NIH HHS R03 AR075886NIAMS NIH HHS T32 AR007258
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Antirheumatic AgentsCOVID-19Rheumatic DiseasesHumansAntirheumatic Agentsantirheumatic agentsarthritis, rheumatoidepidemiologyhealth services research
What OpenQuestion holds
Textmetadata
Read underepoch 390